Free Trial
→ Do this Before Elon’s Reveal on January 29th (From Brownstone Research) (Ad)

CytoDyn Q2 2024 Earnings Report

CytoDyn logo
$0.17 +0.02 (+12.73%)
As of 03:59 PM Eastern
Earnings History

CytoDyn EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CytoDyn Announcement Details

Quarter
Q2 2024
Date
1/16/2024
Time
N/A

Conference Call Resources

CytoDyn Earnings Headlines

CytoDyn Inc.: December 2024 Letter to Shareholders
December 17, 2024 | finanznachrichten.de
December 2024 Letter to Shareholders
December 17, 2024 | globenewswire.com
Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
January 21, 2025 | Brownstone Research (Ad)
CytoDyn Inc. (CYDY) Stock Price, News, Quote & History - Yahoo Finance
December 11, 2024 | finance.yahoo.com
Former Portland area biotech CEO is convicted in securities fraud scheme
December 11, 2024 | bizjournals.com
CytoDyn CEOs Caught in Fraud Scheme to Inflate Stock Prices
December 11, 2024 | msn.com
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY), a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

View CytoDyn Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles